Filter Results
:
(96)
Show Results For
-
All HBS Web
(516)
- Faculty Publications (96)
Show Results For
-
All HBS Web
(516)
- Faculty Publications (96)
- May 2005
- Supplement
GlaxoSmithKline: Reorganizing Drug Discovery (B)
By: Robert S. Huckman and Eli Strick
Supplements the (A) case.
View Details
Keywords:
Mergers and Acquisitions;
Decisions;
Operations;
Performance;
Research and Development;
Restructuring;
Organizations;
Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (B)." Harvard Business School Supplement 605-075, May 2005.
- October 2004 (Revised July 2010)
- Case
Product Team Cialis: Getting Ready to Market
By: Elie Ofek
Lilly and ICOS are preparing for the launch of a new drug, Cialis, to compete against Viagra. To position against the incumbent firm Pfizer, which developed and markets Viagra, and other newcomers into the erectile dysfunction market, they must determine how best to...
View Details
Keywords:
Communication Strategy;
Marketing Strategy;
Product Launch;
Product Positioning;
Competition;
Competitive Advantage;
Segmentation;
Pharmaceutical Industry
Ofek, Elie. "Product Team Cialis: Getting Ready to Market." Harvard Business School Case 505-038, October 2004. (Revised July 2010.)
- June 2004
- Case
Aventis SA (A): Planning for a Merger
By: Joshua D. Margolis and Carin-Isabel Knoop
Eight executives at Hoechst and Rhone-Poulenc must make four crucial decisions on the eve of merging their companies to become Aventis--what would become the world's third largest pharmaceutical firm. In addition to formulating a vision and strategy, the two firms must...
View Details
Keywords:
Problems and Challenges;
Mergers and Acquisitions;
Horizontal Integration;
Organizational Design;
Organizational Culture;
Pharmaceutical Industry;
United States
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (A): Planning for a Merger." Harvard Business School Case 404-003, June 2004.
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will...
View Details
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
- August 2003
- Teaching Note
Pharmacyclics: Financing Research and Development (TN)
By: Malcolm P. Baker and Richard S. Ruback
Teaching Note for (9-201-056).
View Details
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations.
View Details
Keywords:
Health Disorders;
Research and Development;
Genetics;
Pharmaceutical Industry;
Pharmaceutical Industry
Herzlinger, Regina E., and Marc Aquino. "Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene." Harvard Business School Case 303-044, June 2003. (Revised March 2008.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Pharmaceutical Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (B)
By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this...
View Details
Keywords:
Decision Making;
Moral Sensibility;
Innovation and Invention;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research and Development;
Pharmaceutical Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (B)." Harvard Business School Case 603-044, April 2003. (Revised October 2004.)
- December 2002
- Article
Knowledge Seeking and Location Choice of Foreign Direct Investment in the United States
By: Juan Alcacer and Wilbur Chung
To what extent do firms go abroad to access technology available in other locations? This paper examines whether and when state technical capabilities attract foreign investment in manufacturing from 1987-1993. We find that on average state R&D intensity does not...
View Details
Keywords:
Knowledge Acquisition;
Foreign Direct Investment;
Research and Development;
Information Technology;
Production;
Geographic Location;
United States
Alcacer, Juan, and Wilbur Chung. "Knowledge Seeking and Location Choice of Foreign Direct Investment in the United States." Management Science 48, no. 12 (December 2002): 1534–1554.
- November 2002
- Compilation
Four Principles of Biomedical Ethics: Definitions and Examples
By: Sandra J. Sucher
Introduces four principles of biomedical ethics, excerpted from Principles of Biomedical Ethics, Tom L. Beauchamp and James F. Childress (Oxford University Press, 2001). The principles provide a conceptual framework for the analysis and resolution of moral problems...
View Details
Keywords:
Framework;
Moral Sensibility;
Health Care and Treatment;
Distribution;
Problems and Challenges;
Research;
Emotions;
Management Analysis, Tools, and Techniques;
Pharmaceutical Industry;
Pharmaceutical Industry
Sucher, Sandra J. "Four Principles of Biomedical Ethics: Definitions and Examples." Harvard Business School Compilation 603-079, November 2002.
- February 2001 (Revised July 2006)
- Case
Discovering the Future: R&D Strategy at Merck
By: Gary P. Pisano
Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate?
View Details
Pisano, Gary P. "Discovering the Future: R&D Strategy at Merck." Harvard Business School Case 601-086, February 2001. (Revised July 2006.)
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more...
View Details
Keywords:
Valuation;
Cash Flow;
Financing and Loans;
Business Startups;
Financial Strategy;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- 2001
- Chapter
Publicly Funded Science and the Productivity of the Pharmaceutical Industry
By: Rebecca Henderson and Ian Cockburn
U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While...
View Details
Keywords:
Public Sector;
Science-Based Business;
Research and Development;
Sovereign Finance;
Pharmaceutical Industry
Henderson, Rebecca, and Ian Cockburn. "Publicly Funded Science and the Productivity of the Pharmaceutical Industry." In Innovation Policy and the Economy, Volume 1, edited by Adam B. Jaffe, Josh Lerner, and Scott Stern, 1–34. MIT Press, 2001.
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca Henderson and Iain Cockburn
Henderson, Rebecca, and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001).
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords:
Competency and Skills;
Research and Development;
Pharmaceutical Industry;
Pharmaceutical Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 2000
- Chapter
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Keywords:
Competency and Skills;
Measurement and Metrics;
Research and Development;
Innovation and Invention;
Pharmaceutical Industry
Henderson, Rebecca M., and Iain Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Chap. 6 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter. New York: Oxford University Press, 2000.
- February 2000 (Revised October 2000)
- Case
Kendle International Inc.
By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs
Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and...
View Details
Keywords:
Acquisition;
Financing and Loans;
Venture Capital;
Stock Options;
Banks and Banking;
Debt Securities;
International Finance;
Financial Strategy;
Management Skills;
Private Ownership;
Initial Public Offering;
Pharmaceutical Industry;
Pharmaceutical Industry
Crane, Dwight B., Paul W. Marshall, and Indra Reinbergs. "Kendle International Inc." Harvard Business School Case 200-033, February 2000. (Revised October 2000.)
- December 1999
- Case
Agrochemicals at Ciba-Geigy AG (A)
By: Michael L. Tushman, Wendy Smith and Daniel Radov
After spending five years to develop a revolutionary product, the director of Ciba-Geigy's fungicide research department is handed an unfavorable market study. The case details the R&D process for the new product, including information on corporate partnerships,...
View Details
Keywords:
Agribusiness;
Plant-Based Agribusiness;
Research and Development;
Innovation and Invention;
Innovation Strategy;
Product Launch;
Marketing Channels;
Change Management;
Product Development;
Business Processes;
Organizational Structure;
Corporate Accountability;
Pharmaceutical Industry;
Pharmaceutical Industry
Tushman, Michael L., Wendy Smith, and Daniel Radov. "Agrochemicals at Ciba-Geigy AG (A)." Harvard Business School Case 400-022, December 1999.
- December 1999 (Revised January 2000)
- Case
Agrochemicals at Ciba-Geigy AG (B)
By: Michael L. Tushman, Wendy Smith and Daniel Radov
Focuses on Pierre Urech's efforts to change the division structure at Ciba-Geigy to facilitate the marketing of the new product. Details the relationships Urech cultivates and the strategy he pursues as "product champion." Also describes the restructuring of the...
View Details
Keywords:
Change Management;
Innovation Strategy;
Innovation and Management;
Leadership Development;
Leadership Style;
Research and Development;
Marketing Strategy;
Goods and Commodities;
Product Development;
Pharmaceutical Industry;
Switzerland
Tushman, Michael L., Wendy Smith, and Daniel Radov. "Agrochemicals at Ciba-Geigy AG (B)." Harvard Business School Case 400-023, December 1999. (Revised January 2000.)
- 1999
- Chapter
The Economics of Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "The Economics of Drug Discovery." Chap. 5 in Pharmaceutical Innovation, edited by Ralph Landau, Basil Achilladelis, and Alexander Scriabine, 308–331. Philadelphia: Chemical Heritage Press, 1999.